Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 in EGFR-low Glioblastoma
NCT04629209Phase 2Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dordaviprone in glioblastoma (GBM), sponsored by Masonic Cancer Center. Planned start Jun 2024; status: withdrawn.
02
Drugs
dordaviprone
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04629209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629209.